Select language:  
1800 620 420
Close menu

CEO Message

Grateful. It’s a simple but powerful way to describe how we feel about you. As the world continues to navigate the ever-evolving COVID-19 pandemic, your care for Australians facing blood cancer remains unwavering.

Now more than ever, you’ve enabled the Leukaemia Foundation to be there for our blood cancer community in all the best ways possible. Your generosity has made sure all Australians living with blood cancer can access support driven by their individual needs.

Our face-to-face care is now enhanced with innovative new digital services and it’s been incredible to see people connecting and receiving support online across our country, be it from a farm, office, or hospital bed.

Equally important to support is hope. We recently celebrated the breakthrough listing of venetoclax on the Pharmaceutical Benefits Scheme for people living with acute myeloid leukaemia (AML). This development gives affordable access to a new treatment possibility for around 340 Australians with AML each year who might otherwise have run out of options. Thanks to our supporters, the Leukaemia Foundation contributed to the early development of venetoclax. And now, incredibly, we see that support transforming into real hope for families.

We’re so grateful to have you standing with us, putting patients first.

Leukaemia Foundation CEO Chris Tanti
Chris Tanti
Leukaemia Foundation



Last updated on March 4th, 2022

Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.